MED vs. LW, NOMD, USNA, NUS, NATR, VERU, EL, IPAR, PBH, and HLF
Should you be buying Medifast stock or one of its competitors? The main competitors of Medifast include Lamb Weston (LW), Nomad Foods (NOMD), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Veru (VERU), Estee Lauder Companies (EL), Interparfums (IPAR), Prestige Consumer Healthcare (PBH), and Herbalife (HLF).
Medifast vs. Its Competitors
Medifast (NYSE:MED) and Lamb Weston (NYSE:LW) are both consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.
Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.
Medifast presently has a consensus price target of $16.50, indicating a potential upside of 13.17%. Lamb Weston has a consensus price target of $67.73, indicating a potential upside of 27.79%. Given Lamb Weston's stronger consensus rating and higher possible upside, analysts plainly believe Lamb Weston is more favorable than Medifast.
Lamb Weston has a net margin of 5.74% compared to Medifast's net margin of -1.29%. Lamb Weston's return on equity of 27.25% beat Medifast's return on equity.
In the previous week, Lamb Weston had 12 more articles in the media than Medifast. MarketBeat recorded 18 mentions for Lamb Weston and 6 mentions for Medifast. Medifast's average media sentiment score of 0.70 beat Lamb Weston's score of 0.57 indicating that Medifast is being referred to more favorably in the media.
Medifast has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Lamb Weston has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
95.5% of Medifast shares are owned by institutional investors. Comparatively, 89.6% of Lamb Weston shares are owned by institutional investors. 2.9% of Medifast shares are owned by company insiders. Comparatively, 0.7% of Lamb Weston shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Lamb Weston beats Medifast on 12 of the 16 factors compared between the two stocks.
Get Medifast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medifast Competitors List
Related Companies and Tools
This page (NYSE:MED) was last updated on 7/6/2025 by MarketBeat.com Staff
